modelCabazitaxel
Extends from Pharmacolibrary.Drugs.ATC.L.L01CD04.
Information
| name: | Cabazitaxel | |
| ATC code: | L01CD04 | route: | intravenous |
| compartments: | 3 | |
| dosage: | 25 | mg |
| volume of distribution: | 48.5 | L |
| clearance: | 48.5 | L/h |
| other parameters in model implementation | ||
Cabazitaxel is a semisynthetic taxane antineoplastic agent used primarily for the treatment of metastatic castration-resistant prostate cancer. It works by inhibiting microtubule depolymerization, thereby resulting in cell cycle arrest and apoptosis in cancer cells. Cabazitaxel is approved for use, particularly in patients previously treated with docetaxel.
Pharmacokinetics
Pharmacokinetic parameters from adult cancer patients (predominantly male, median age ~68 years) receiving cabazitaxel 25 mg/m² as a 1-hour intravenous infusion.
References
Nozawa, M, et al., & Kakehi, Y (2015). Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. International journal of clinical oncology 20(5) 1026–1034. DOI:10.1007/s10147-015-0820-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25809824
Valsalakumari, R, et al., & Iversen, TG (2024). Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants. International journal of nanomedicine 19 3009–3029. DOI:10.2147/IJN.S450283 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38562610
Mukai, H, et al., & Suzuki, K (2014). Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 73(4) 703–710. DOI:10.1007/s00280-014-2394-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/24488323
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.Volume | Vdp2 (from PK_3C) | Vdp2PerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | Vdp2PerKg (from PK_3C) | 0.9 | Volume of distribution peripheral 2 (l/kg) |
| Pharmacolibrary.Types.VolumeFlowRate | k13 (from PK_3C) | 1 | intercompartmental 1-3 clearance (l/min) |
| Pharmacolibrary.Types.VolumeFlowRate | k31 (from PK_3C) | 1 | intercompartmental 3-1 clearance (l/min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) | ||
| Interfaces.ConcentrationPort_b | perihperal2Cport (from PK_3C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral2 (from PK_3C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral1 (from PK_3C) | ||
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer1 (from PK_3C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)